The word incretin is frequently used as though it named a single mechanism. It names a class of gut-derived hormones that enhance insulin secretion after nutrient intake — and within that class, GLP-1 and GIP behave differently from one another. Glucagon, often discussed alongside them in multi-receptor strategies, is counter-regulatory and different again.
Three receptors, three distributions, three sets of downstream effects. Treating them as interchangeable produces claims the biology does not support.
Conversation one: GLP-1
GLP-1 is secreted from intestinal L-cells in response to nutrient intake. It enhances insulin secretion in a glucose-dependent manner, suppresses glucagon during hyperglycemia, slows gastric emptying, and acts on central pathways involved in satiety. The glucose dependence is important: the insulinotropic effect is amplified when glucose is elevated and diminished when it is not.
- 01Pancreatic: Glucose-dependent enhancement of insulin secretion; suppression of glucagon when glucose is high.
- 02Gastrointestinal: Slowed gastric emptying, which alters the rate of nutrient delivery to the intestine.
- 03Central: Effects on appetite and satiety circuits documented in both preclinical and clinical work.
Conversation two: GIP
GIP is secreted from intestinal K-cells and is also insulinotropic in a glucose-dependent way, but its wider profile diverges from GLP-1. It has documented effects on adipose tissue, context-dependent effects on glucagon secretion, and central actions that are an active research subject. Its role in combination approaches has been reconsidered substantially in recent years.
Evidence note: The pharmacology of GIP receptor engagement — including the ongoing question of agonism versus antagonism in combination therapy — remains under active investigation. Statements about GIP should be read as more provisional than those about GLP-1.
Conversation three: glucagon
Glucagon is not an incretin. It is a counter-regulatory hormone secreted by pancreatic alpha cells that maintains circulating glucose during fasting by promoting hepatic glucose production. Interest in glucagon receptor activity within multi-receptor strategies stems from its associations with energy expenditure and hepatic lipid metabolism — balanced against the fact that glucagon raises glucose.
The three receptors are not three doses of the same signal. They are three different jobs, and one of them pulls in the opposite direction.
Why the distinction changes how claims read
| Receptor | Primary role | Why it is not interchangeable |
|---|---|---|
| GLP-1 | Glucose-dependent insulin secretion, satiety, gastric emptying | Best-characterized of the three; the reference point the category is measured against |
| GIP | Glucose-dependent insulin secretion, adipose and central effects | Distinct tissue distribution; combination pharmacology still being defined |
| Glucagon | Hepatic glucose output during fasting, energy expenditure | Counter-regulatory — engaging it requires balancing against glycemic effect |
Table 1 — The three receptor families most often grouped under a single label, and the distinct roles they carry.
A product or therapy described as supporting 'the incretin system' is describing a system with internal structure. The useful question is which of the three conversations is addressed, on what evidence, and what is claimed about the interaction between them.
- 01Ask which receptors are named, not whether the category is named.
- 02Ask what evidence exists at the level of the specific compound rather than the class.
- 03Ask how the counter-regulatory element is accounted for when glucagon is part of the discussion.
Where the hormones come from and when
GLP-1 and GIP are secreted by distinct enteroendocrine cell populations distributed differently along the intestine. K-cells, which release GIP, are concentrated in the proximal small intestine and respond rapidly to nutrients arriving from the stomach. L-cells, which release GLP-1, are more abundant distally, and their secretion pattern reflects nutrients reaching the lower intestine as well as neural and hormonal signals initiated earlier.
This anatomical difference means the two hormones have different time courses after a meal, and that anything altering the rate of nutrient transit — including GLP-1's own effect on gastric emptying — changes the relationship between them. The axis is not a set of parallel channels; it is a sequence with internal feedback.
- 01K-cells: Proximal small intestine; GIP secretion follows nutrient arrival relatively early.
- 02L-cells: More distal distribution; GLP-1 secretion reflects both direct nutrient contact and upstream signaling.
- 03Transit dependence: Gastric emptying rate shapes the timing and magnitude of both responses.
- 04Feedback: GLP-1 slows emptying, which alters the nutrient stimulus driving subsequent secretion.
The incretin effect, quantified
The observation that founded this field is straightforward: oral glucose produces a substantially greater insulin response than an intravenous infusion producing the same blood glucose concentration. The difference is attributable to gut-derived hormones, and in healthy physiology it accounts for a majority of the insulin response to an oral load.
In type 2 diabetes this incretin effect is markedly reduced. Whether that reduction is cause or consequence has been debated extensively, and the current view treats it as part of the disease process rather than as its origin. It remains one of the clearest demonstrations that the gut is a metabolic signaling organ rather than a passive absorptive surface.
Evidence note: The magnitude of the incretin effect varies with the size of the glucose load and the population studied. Its reduction in type 2 diabetes is consistently observed; the mechanism underlying that reduction is still being defined.
Glucose dependence and why it matters
Both GLP-1 and GIP enhance insulin secretion in a glucose-dependent manner: the effect is amplified when glucose is elevated and diminishes as glucose falls. This property is a feature of the physiology rather than an incidental detail, because it means the signal is self-limiting — insulin secretion is not driven when glucose is already low.
GLP-1's suppression of glucagon shows the same conditionality. It suppresses glucagon during hyperglycemia while leaving the counter-regulatory response to low glucose intact. Any description of these pathways that omits glucose dependence describes a different and more hazardous physiology than the one that exists.
Why GIP is the contested one
GIP has the most complicated history of the three. It is unambiguously insulinotropic in healthy physiology, but its effects on adipose tissue, its context-dependent influence on glucagon, and its central actions have made its role in combination approaches genuinely unsettled. Both agonism and antagonism at the GIP receptor have been pursued as strategies, with arguments and data on each side.
This is worth stating plainly because it is unusual: the field contains active, credible disagreement about the direction of the intervention, not merely its magnitude. Any confident claim about GIP should be read against that background.
- 01Established: GIP is an incretin hormone that enhances glucose-dependent insulin secretion.
- 02Documented: GIP receptors are present in adipose tissue and in central nervous system regions relevant to appetite.
- 03Contested: Whether receptor agonism or antagonism produces better metabolic outcomes in combination approaches.
- 04Unsettled: The mechanism by which GIP receptor engagement contributes to the effects observed with dual agonists.
Glucagon: the counter-regulatory member
Including glucagon in a discussion of incretins requires care, since it is not one. It is secreted by pancreatic alpha cells rather than the gut, and its principal role is to raise glucose during fasting by promoting hepatic glucose production. Interest in glucagon receptor activity within multi-receptor strategies rests on associations with energy expenditure and hepatic lipid handling.
The tension is explicit: the same receptor activity associated with increased energy expenditure also raises hepatic glucose output. Strategies engaging it must balance those effects, and the balance is precisely what remains under investigation. Presenting glucagon receptor activity as straightforwardly beneficial omits the constraint that defines the research question.
Two of these signals lower glucose conditionally. The third raises it. That is not a detail to be smoothed over in summary.
What multi-receptor strategies are actually testing
The hypothesis behind engaging several receptors is that metabolic regulation is distributed across pathways that affect overlapping but distinct processes, so coordinated engagement may achieve more than maximizing a single one. This is biologically reasonable and has clinical support for specific dual-agonist compounds. It is not a general principle that more targets produce better outcomes.
- 01Compound-level evidence: Results attach to specific molecules with specific receptor potencies and pharmacokinetics, not to the category.
- 02Ratio matters: The relative activity at each receptor is a design variable, and different ratios produce different profiles.
- 03Safety is part of the endpoint: Tolerability and glycemic safety determine whether an effect is usable, not only whether it exists.
- 04Duration matters: Long-term comparative data remain limited for the newest multi-receptor approaches.
Why category-level claims fail
Agents acting on these receptors differ from one another in ways that determine their effects: relative potency at each receptor, the ratio between those potencies, half-life, route of administration, and the tissues their pharmacokinetics allow them to reach. Two compounds described by the same category label can produce measurably different outcomes in clinical study.
This is why evidence in this field attaches to compounds rather than to categories, and why a mechanism shared with an approved agent does not transfer that agent's evidence to anything else. The shared mechanism establishes plausibility; the specific compound has to be studied on its own terms.
- 01Receptor ratio: The balance of activity across receptors is a design variable with distinct consequences.
- 02Pharmacokinetics: Half-life and distribution determine which tissues are engaged and for how long.
- 03Formulation and route: These change exposure profiles even for identical molecules.
- 04Consequence: Evidence is compound-specific; category membership is not evidence.
Reading claims about the axis
The single most useful discipline when evaluating a claim in this area is to insist on specificity. A statement about supporting the incretin system is not evaluable. A statement naming a receptor, a tissue, a measured endpoint, and a study population is.
- 01Which of the three receptors is named, and is glucose dependence acknowledged?
- 02Is the evidence at the level of the specific compound, or borrowed from the category?
- 03If glucagon is included, how is the counter-regulatory effect accounted for?
- 04Is the endpoint clinical, or a mechanistic intermediate?
- 05Is the comparison against placebo, against another compound, or against nothing at all?
Degradation and duration
Native GLP-1 has an extremely short circulating half-life, cleared rapidly by the enzyme dipeptidyl peptidase-4 and by renal elimination. GIP is degraded by the same enzyme. This rapid turnover is why the endogenous hormones act as meal-associated pulses rather than sustained signals, and it explains why an entire class of therapeutics targets the degrading enzyme rather than the receptors themselves.
The distinction between raising endogenous hormone levels modestly and administering a degradation-resistant receptor agonist is substantial. The two approaches produce different concentration profiles, different degrees of receptor occupancy, and different clinical effects, despite acting on the same axis. Conflating them is a frequent source of overstated inference.
- 01Endogenous hormones: Short half-life; meal-associated pulses; physiological concentration range.
- 02Enzyme inhibition: Modest elevation of native hormone levels within a broadly physiological range.
- 03Receptor agonists: Degradation-resistant molecules producing sustained occupancy well above physiological levels.
- 04Implication: Evidence from one approach does not transfer to another acting on the same receptors.
The gut-brain component
A substantial part of GLP-1's effect on appetite is mediated through neural routes rather than through circulating hormone reaching the brain. Vagal afferents in the intestinal wall express GLP-1 receptors and signal to brainstem nuclei, and populations of neurons within the central nervous system produce GLP-1 locally. The peripheral and central sources are distinct systems that share a molecule.
This matters when a claim describes effects on appetite. Peripheral concentration measurements do not establish central engagement, and the routes involved differ in accessibility for both natural and pharmacological signals.
Why the distinction is the point
Treating the incretin axis as one signal produces two predictable errors: assuming that engaging one receptor covers the others, and assuming that engaging all three is simply additive. The biology supports neither. Three receptors, three distributions, three sets of downstream effects — and one of them pulling in the opposite direction — is a more demanding description, and it is the one the literature actually supports.
This article is educational and describes incretin and glucagon biology as characterized in the published literature. It is not a treatment recommendation and not a claim of clinical effect for any product.